|
1
|
Wiersinga WM and Bartalena L: Epidemiology
and prevention of Graves' ophthalmopathy. Thyroid. 12:855–860.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wiersing WM: Advances in treatment of
active, moderate- to-severe Graves' ophthalmopathy. Lancet Diabetes
Endocrinol. 5:134–142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stiebel-Kalish H, Robenshtok E,
Hasanreisoglu M, Ezrachi D, Shimon I and Leibovici L: Treatment
modalities for Graves' ophthalmopathy: Systematic review and
meta-analysis. J Clin Endocrinol Metab. 94:2708–2716. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gao G, Dai J, Qian Y and Ma F:
Meta-analysis of methylprednisolone pulse therapy for Graves'
ophthalmopathy. Clin Exp Ophthalmol. 42:769–777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartalena L, Baldeschi L, Dickinson A,
Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P,
Boboridis K, Boschi A, et al: Consensus statement of the European
Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J
Endocrinol. 158:273–285. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zang S, Ponto KA and Kahaly GJ: Clinical
review: Intravenous glucocorticoids for Graves' orbitopathy:
Efficacy and morbidity. J Clin Endocrinol Metab. 96:320–332. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Whittier X and Saag KG:
Glucocorticoid-induced Osteoporosis. Rheum Dis Clin North Am.
42:177–168. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartley GB and Gorman CA: Diagnostic
criteria for Graves' ophthalmopathy. Am J Ophthalmol. 119:792–795.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bartalena L, Baldeschi L, Boboridis K,
Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM;
European Group on Graves, ; et al: The 2016 european Thyroid
Association/European Group on Graves' Orbitopathy guidelines for
the management of Graves' orbitopathy. Eur Thyroid J. 5:9–26. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bahn R: High-dose intravenous
glucocorticoid therapy for Graves' ophthalmopathy: Where are we
now? Thyroid. 22:1–2. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
San Miguel I, Arenas M, Carmona R, Rutllan
J, Medina-Rivero F and Lara P: Review of the treatment of Graves'
ophthalmopathy: The role of the new radiation techniques. Saudi J
Ophthalmol. 32:139–145. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Adler RA: Glucocorticoid-induced
osteoporosis: Management challenges in older patients. J Clin
Densitom. 22:20–24. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Compston J: Glucocorticoid-induced
osteoporosis: An update. Endocrine. 61:7–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yongxin H U, Li S, Shaofeng X, et al:
Analysis of bone metabolism in patients with Graves'
orbitopathy[J]. Jiangsu Medical Journal. 42:1875–1877. 2016.
|
|
15
|
Uedasakane Y, Kanamoto N, Fushimi Y,
Tanaka-Mizuno S, Yasuno S, Miura M, Sone M, Yasoda A, Okada T,
Togashi K, et al: Overall safety and efficacy of high-dose and
low-dose intravenous glucocorticoid therapy in patients with
moderate-to-severe active Graves' ophthalmopathy. Endocr J.
63:703–714. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu X, Wang S, Qin L, Qiang W, Dahal M,
Fan P, Gao S and Shi B: Short and long-term effects of high-dose
intravenous methylprednisolone pulse therapy on thyroid-associated
ophthalmopathy. Exp Ther Med. 12:901–908. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Miśkiewicz P, Kryczka A, Ambroziak U,
Rutkowska B, Główczyńska R, Opolski G, Kahaly G and Bednarczuk T:
Is high dose intravenous methylprednisolone pulse therapy in
patients with Graves' orbitopathy safe? Endokrynol Pol. 65:402–413.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu Y, Dimango E, Bucovsky M, Agarwal S,
Nishiyama K, Guo XE, Shane E and Stein EM: Abnormal
microarchitecture and stiffness in postmenopausal women using
chronic inhaled glucocorticoids. Osteoporos Int. 29:2121–2127.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leib ES and Winzenrieth R: Bone status in
glucocorticoid-treated men and women. Osteoporos Int. 27:39–48.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen L, Ma C, Shuai B and Yang Y: Effects
of 1,25-dihydroxyvitamin D3 on the local bone renin-angiotensin
system in a murine model of glucocorticoid-induced osteoporosis.
Exp Ther Med. 13:3297–3304. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kenanidis E, Potoupnis ME, Kakoulidis P,
Leonidou A, Sakellariou GT, Sayegh FE and Tsiridis E: Management of
glucocorticoid-induced osteoporosis: Clinical data in relation to
disease demographics, bone mineral density and fracture risk.
Expert Opin Drug Saf. 14:1035–1053. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shymanskyi I, Lisakovska O, Mazanova A,
Labudzynskyi D and Veliky M: Vitamin D3 modulates impaired
crosstalk between RANK and glucocorticoid receptor signaling in
bone marrow cells after chronic prednisolone administration. Front
Endocrinol (Lausanne). 9:3032018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sato AY, Richardson D, Cregor M, Davis HM,
Au ED, McAndrews K, Zimmers TA, Organ JM, Peacock M, Plotkin LI and
Bellido T: Glucocorticoids induce bone and muscle atrophy by
tissue-specific mechanisms upstream of E3 ubiquitin ligases.
Endocrinology. 158:664–677. 2017.PubMed/NCBI
|
